Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LBVD vs Eupenta + Imovax Polio in Healthy Adults
NCT03208101Phase 1Completed
- Sponsor
- LG Chem
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lomustine + bleomycin + vinblastine + doxorubicin in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by LG Chem. Primary endpoints: Number of subjects with immediate reactions, Number of subjects with solicited adverse events at 14 days and 1 more. Started Jul 2017; status: completed.
02
Drugs
lomustine + bleomycin + vinblastine + doxorubicin
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on NCT03208101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208101.